Table 1 Patient, tumor and treatment characteristics
SRS group (67 patients) | FSRT group (27 patients) | ANOVA p-value | |||||
|---|---|---|---|---|---|---|---|
N (%) | mean/ median | range | N (%) | mean/ median | range | ||
Patients | |||||||
Age | 67 | 58/59 | 34–80 | 27 | 48/51 | 27–79 | < 0.001 |
Gender | 0.2 | ||||||
Male | 32 | 9 | |||||
Female | 35 | 18 | |||||
Hearing | |||||||
GR baseline class | 0.01 | ||||||
1 | 7 (10,4) | 13 (48.1) | |||||
2 | 30 (44.8) | 7 (25.9) | |||||
3 | 28 (41.8) | 5 (18.5) | |||||
4 | 2 (2.9) | 2 (7.4) | |||||
Δ PTA (dB/month) | 1.35/0.95 | −0.86-11.13 | 2.9/1.65 | −0.65-28 | 0.05 | ||
PTA pre-treatment (dB) | 48.2/46.3 | 1.3–96 | 36/34 | 3.7–94 | 0.02 | ||
SDS pre-treatment (%) | 78/85 | 18–100 | 83/94 | 3–100 | 0.38 | ||
Tumors | |||||||
Tumor side | |||||||
Left | 37 | 14 | 0.8 | ||||
Right | 30 | 13 | |||||
Tumor volume Pre-treatment (ml) | 3.0/2.36 | 0.37–12.82 | 7.4/6.8 | 0.24–20.1 | 0.003 | ||
Tumor diameter CPA (cm) | 1.7/1.56 | 0.64/3.34 | 2.4/2.56 | 0.67/4.22 | < 0.001 | ||
Tumor diameter IAC (cm) | 0.88/0.93 | 0.15/1.39 | 0.83/0.93 | 0/1.41 | 0.453 | ||
Radiation | |||||||
Cochlear volume (ml) | 0.17/0.17 | 0.08–0.31 | 0.22/0.22 | 0.17–0.36 | < 0.001 | ||
Max cochlear dose EQD2 | 3578/3990 | 448–6693 | 4623/4840 | 3428–5258 | < 0.001 | ||
Mean cochlear dose EQD2 | 1054/736 | 114–3211 | 3569/3781 | 1355–4866 | < 0.001 | ||
V90 EQD2 (mm3) | 4/0 | 0–51 | 65/50 | 0–256 | < 0.001 | ||
Follow-up time (months) | 37/36 | 4.8–121 | 61/63 | 8.3–123 | < 0.001 | ||